The impact of aripiprazole on neurocognitive function in individuals at clinical high risk for psychosis: A comparison with olanzapine and non-antipsychotic treatment

作者：Jianzhong Zeng, Andrea Raballo, JiaYi Ye, YuQing Gao, Wenjun Su, YanYan Wei, XiaoChen Tang, Lihua Xu, YeGang Hu, Dan Zhang, HuiRu Cui, Yingying Tang, XiaoHua Liu, HaiChun Liu, Tao Chen, Chunbo Li, Jijun Wang, Tianhong Zhang · 发表于：European Psychiatry · 年份：2025 · DOI：10.1192/j.eurpsy.2025.2459 · 被引用次数：3 · 研究领域：Schizophrenia research and treatment、Mental Health and Psychiatry、Dementia and Cognitive Impairment Research

BACKGROUND: Clinical high risk for psychosis (CHR) is often managed with antipsychotic medications, but their effects on neurocognitive performance and clinical outcomes remain insufficiently explored. This study investigates the association between aripiprazole and olanzapine use and cognitive and clinical outcomes in CHR individuals, compared to those receiving no antipsychotic treatment. METHODS: A retrospective analysis was conducted on 127 participants from the Shanghai At Risk for Psychosis (SHARP) cohort, categorized into three groups: aripiprazole, olanzapine, and no antipsychotic treatment. Neurocognitive performance was evaluated using the MATRICS Consensus Cognitive Battery (MCCB), while clinical symptoms were assessed through the Structured Interview for Prodromal Syndromes (SIPS) at baseline, 8 weeks, and one year. RESULTS: The non-medicated group demonstrated greater improvements in cognitive performance, clinical symptoms, and functional outcomes compared to the medicated groups. Among the antipsychotic groups, aripiprazole was associated with better visual learning outcomes than olanzapine. Improvements in neurocognition correlated significantly with clinical symptom relief and overall functional gains at follow-up assessments. CONCLUSIONS: These findings suggest potential associations between antipsychotic use and cognitive outcomes in CHR populations while recognizing that observed differences may reflect baseline illness severity rather than medication effe...